Overcoming immunosuppression to enhance a p53MVA vaccine
Open accessAbstract
A Phase I trial of a p53-targeting modified vaccinia Ankara (p53MVA) vaccine in patients afflicted with refractory gastrointestinal cancers demonstrated enhanced T-cell recognition of p53 following vaccination. However, this effect was transient suggesting that p53MVA requires combination with immunomodulatory agents to deliver clinical benefit. Here, we outline our rationale for combining p53MVA with immunomodulatory chemotherapy in a forthcoming trial.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Hardwick's group conducted two early-phase clinical trials of MVAp53; MVAp53 induced CD8+ and CD4+ T cell responses in patients with refractory gastrointestinal cancer and ovarian cancer.
“Later in 2014 and 2018, Hardwick’s group conducted two early-phase clinical trials involving a modified vaccinia virus ankara vaccine encoding wtp53 (MVAp53 (253)). The studies showed that MVAp53 could induce CD8+ and CD4+ T cell responses in patients with refractory gastrointestinal cancer and ovarian cancer, respectively.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [591]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · see citing works
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,324 · see citing works
Leffers, N., Lambeck, A. J. A., Gooden, M. J. M., Hoogeboom, B. N., Wolf, R., Hamming, I. L. E., Hepkema, B. G., Willemse, P. H. B., Molmans, B. H. W., Hollema, H., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24597 · Cited by 141 · see citing works
Kaida, M., Morita‐Hoshi, Y., Soeda, A., Wakeda, T., Yamaki, Y., Kojima, Y., Ueno, H., Kondo, S., Morizane, C., Ikeda, M., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181fb65b9 · Cited by 118 · see citing works
Hirooka, Y., Ito, A., Kawashima, H., Hara, K., Nonogaki, K., Kasugai, T., Ohno, E., Ishikawa, T., Matsubara, H., Ishigami, M., et al. (2009) · Pancreas · doi:10.1097/mpa.0b013e318197a9e3 · Cited by 115 · see citing works
Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: A single‐arm phase II study
Vermeij, R., Leffers, N., Hoogeboom, B. N., Hamming, I. L. E., Wolf, R., Reyners, A. K. L., Molmans, B. H. W., Hollema, H., Bart, J., Drijfhout, J. W., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27388 · Cited by 97 · see citing works
Hirooka, Y., Ito, A., Kawashima, H., Hara, K., Nonogaki, K., Kasugai, T., Ohno, E., Ishikawa, T., Matsubara, H., Ishigami, M., et al. (2009) · Suizo · doi:10.2958/suizo.24.632 · Cited by 88 · see citing works
Homma, Y., Taniguchi, K., Nakazawa, M., Matsuyama, R., Mori, R., TAKEDA, K., Ichikawa, Y., Tanaka, K., & Endo, I. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1079-0 · Cited by 83 · see citing works
Soeda, A., Morita‐Hoshi, Y., Makiyama, H., Morizane, C., Ueno, H., Ikeda, M., Okusaka, T., Yamagata, S., Takahashi, N. K., Hyodo, I., et al. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp112 · Cited by 68 · see citing works
Tjomsland, V., Spångéus, A., Sandström, P., Borch, K., Messmer, D., & Larsson, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013441 · Cited by 68 · see citing works
Hardwick, N. R., Carroll, M., Kaltcheva, T., Qian, D., Lim, D., Leong, L., Chu, P., Kim, J., Chao, J., Fakih, M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3361 · Cited by 45 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906 · see citing works
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Yuan, Y., Kos, F. J., He, T.-F., Yin, H. H., Li, M., Hardwick, N., Zurcher, K., Schmolze, D., Lee, P., Pillai, R. K., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1363138 · Cited by 23 · see citing works
Self-citation
- Authors
- Hardwick, N., Chung, V., Cristea, M., Ellenhorn, J. D., & Diamond, D. J.
- Affiliations
- Beckman Research Institute (US)
- City Of Hope National Medical Center (US)
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Diamond, Don J
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2014-09
- Volume
- 3
- Issue
- 10
- Pages
- e958949
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC4292557
- OpenAlex
- W2041151816
- Cited by
- 11
- References
- 11
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2018: 2 · 2017: 4 · 2016: 1
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- OncoImmunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- modified vaccinia Ankara, immunosuppression, gastrointestinal cancer, combination immunotherapy, refractory cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
